Shownotes
vitalityPRO
#007 Dr Rui Lopes - The Innovative Breath Test for SIBO, IBS and Gut Health
Dr Rui Lopes is a medical Doctor and Clinical Researcher. Rui’s clinical experience as a physician has allowed him to successfully develop a career in clinical development and research, where he has worked extensively in gastroenterology , respiratory disease and several other therapeutic areas. Rui now leverages his clinical expertise as a Medical Advisor for Owlstone, to guide and advise the development and implementation of healthcare products.
> During our discussion, you’ll discover:
(00:01:16) Who is Dr Lopes
(00:03:57) What is SIBO, and how is it diagnosed/treated
(00:22:33) Ketogenic or low FODMAP diets for SIBO
(00:24:44) Antimicrobials and other alternative treatments for SIBO
(00:28:38) The future of breath testing
(00:30:27) When and how to use Probiotics with gut issues
The vP life Podcast is brought to you by vitalityPRO, a supplement company based in the UK that provides you with the latest in health, anti-ageing and longevity supplementation. What makes vitalityPRO unique is that it third-party tests every product batch for quality, purity, heavy metals and other contaminants. vitalityPRO’s mission is simple: provide you with confidence in the quality and effectiveness of your longevity supplements that focus on restoring your cellular health.
To save on your first order, navigate to the home page and sign up for the newsletter to receive 10% off your first order.
Research Links:
Transcripts
Hello everybody and welcome to the vP Life podcast brought to you by vitalityPRO.
Speaker:My name's Rob and I'll be your host on today's episode.
Speaker:Today we're joined by Dr.
Speaker:Rui Lopes, a medical doctor and clinical researcher who leverages his expertise
Speaker:as the medical advisor for Owlstone Medical, a biomedical company that
Speaker:is aiming to revolutionize the way we test GI disorders including SIBO.
Speaker:During today's episode we take a deep dive into what Owlstone
Speaker:are trying to accomplish and how their breathalyzers work.
Speaker:We then take a step back and explore the world of SIBO, what it is and the various
Speaker:treatment options that are available.
Speaker:As usual we get through a lot in today's episode so be sure to
Speaker:check out the show notes and the transcript should you need them.
Speaker:And I'd like to ask you a little favor.
Speaker:Our podcast is slowly gaining traction and we'd love it if you could leave us a
Speaker:review wherever you listen to podcasts.
Speaker:This will help us grow, reach more people and allow us to host future guests.
Speaker:And with that, on with the show.
Speaker:Hi, Rui.
Speaker:Thank you for joining us on today's episode of the podcast.
Speaker:Would you just quickly like to sort of introduce yourself, who
Speaker:you are and what it is you do?
Speaker:And then we can just sort of take a deeper dive into OMED health as well.
Speaker:Yeah, perfect.
Speaker:Yeah.
Speaker:Thanks, Rob.
Speaker:Uh, it's a pleasure to be here.
Speaker:So, um, The journey where I am today until, um, getting to
Speaker:Owlstone has been nothing but typical for a doctor usually does.
Speaker:Somewhere along the way I kind of drifted away from the NHS, but I started
Speaker:as every doctor starts, completed my studies, um, started working in the
Speaker:NHS as a physician, and I've been there for the past six, seven years.
Speaker:And I've always had this very traditional path for my clinical
Speaker:training and my specialization.
Speaker:But the interest for research was always there for me.
Speaker:And around two years ago, motivated a great deal by the fact that
Speaker:I have two young children, I transitioned onto the industry.
Speaker:And for that, I've leveraged my research knowledge and my clinical experience
Speaker:across a variety of therapeutic areas, including gastroenterology, where I'm now.
Speaker:And this became extremely useful for my role as a medical advisor
Speaker:at Owlstone um, it's a great role.
Speaker:It's a great place to work, uh, particularly when you see the cutting
Speaker:edge research that we produce in breath analysis and, and biomarker analysis.
Speaker:And this grants us the status of, uh, world leaders in breath research, really.
Speaker:And OMED is, is just a brand of Owlstone where.
Speaker:We're pioneering these new breath technologies, such as the OMED
Speaker:breathalyzer, this portable, precise piece of engineering for the monitoring
Speaker:of GI disease, such as SIBO and IMO.
Speaker:Before we sort of dig a bit deeper into OMED, let's just sort of Discuss a
Speaker:bit more about your sort of foray into gastroenterology, what sort of made you
Speaker:choose that as a speciality or what sort of do you to that field specifically as
Speaker:opposed to, I suppose, endocrinology or?
Speaker:Yeah, so I've done throughout my, my clinical training.
Speaker:I've, I've had exposure to lots of, um, uh, therapeutic areas.
Speaker:Gastroenterology was one of them and I've done a lot of research, uh, particularly
Speaker:in, in biomarker analysis in IBD and IBS.
Speaker:And that was really the one of the most interesting pieces of
Speaker:research that I've conducted in the past, in the past few years.
Speaker:And that was a big selling point for me when, when, um, the
Speaker:Owlstone role came, uh, to play.
Speaker:Because it, it landed perfectly with, uh, my experience in biomarker,
Speaker:um, analysis and discovery.
Speaker:Uh, because it's, it's the mainstay of, of, of Owlstone.
Speaker:This, uh, breath biomarker identification and research to try and, and create these
Speaker:new expedited pathways for non invasive diagnostics of very complex diseases.
Speaker:Okay, fair enough.
Speaker:Well, let's dig into the nuts and bolts of it then.
Speaker:Um, I think a lot of people have heard of SIBO, but maybe not a lot of people
Speaker:actually know what it really is.
Speaker:I mean, there are a lot of acronyms out there.
Speaker:You have SIBO, you have SIFO.
Speaker:There are various different types of SIBO.
Speaker:Um, you, there are very different, various different ways of obviously testing it.
Speaker:But just sort of add from a sort of a 50, 000 foot overview, what
Speaker:is SIBO and who does it affect and how is it affecting them?
Speaker:What is this sort of this condition actually doing to people?
Speaker:Yeah.
Speaker:So, so if we look at our, our gut, um, and particularly if we break it down into
Speaker:different parts, small intestine, large intestine, when there's a change in the
Speaker:composition, the density and the function of the organisms that are in the small,
Speaker:present in the small intestine, um, This leads to an imbalance of our microbiota.
Speaker:And the microbiota is this agglomerate of organisms that we have in our GI
Speaker:tract and other places in our body.
Speaker:And SIBO, which stands for small intestinal bacterial overgrowth, is a
Speaker:type of, uh, this imbalance, uh, that we often mention as dysbiosis, which
Speaker:is characterized by an overabundance of bacteria that are usually in the large
Speaker:intestine or in the mouth and throat.
Speaker:And they relocate to a place where they really shouldn't be,
Speaker:which is the small intestine.
Speaker:And when these bacteria are present in the colon, they are usually not harmful.
Speaker:They are part of the normal digestion, so they help breaking
Speaker:down fiber, for example.
Speaker:But, however, when, when the stomach and the small intestine usually, have very few
Speaker:bacteria, and the composition of this, the organisms present here, is very different
Speaker:from the ones from the large intestine.
Speaker:And things like, for example, stomach acid and the movement of the food along the
Speaker:GI tract tends to limit this overgrowth of bacteria in the small intestine.
Speaker:But any impairment to these protective mechanisms can cause SIBO, and SIBO
Speaker:can affect a wide range of individuals.
Speaker:So we believe, according to published literature, it's about one in seven of us,
Speaker:but it's particularly prevalent in those that have underlying conditions such as
Speaker:IBS, diabetes, or they've had abdominal surgery in the past, for example.
Speaker:And the different types of SIBO, as you mentioned, we often categorize
Speaker:it based on the gas that is produced.
Speaker:Uh, predominantly by, uh, the organism, uh, in, involved.
Speaker:So, uh, it could be hydrogen, which is mostly produced in, in SIBO.
Speaker:Methane, which is mostly produced by, uh, these organisms called Archaea,
Speaker:in a condition called IMO, which is often branded together with SIBO.
Speaker:Hydrogen sulfide, for example.
Speaker:And, and there's different, different gases that are produced
Speaker:in, in different situations.
Speaker:And we tend to break it down into different categories of SIBO,
Speaker:but if you look around in the literature, everything is under the
Speaker:conglomerate of, of, of SIBO, really.
Speaker:And, and this, and the development of SIBO can, can occur due to several factors.
Speaker:Yeah, like I said, an impairment of those protective mechanisms will lead to the
Speaker:bacteria accumulating in the wrong place.
Speaker:So things such as impaired gut motility will lead the bacteria to start, start
Speaker:accumulating in the small intestine.
Speaker:abnormalities in the structure of the, of the GI tract, disruptions of the
Speaker:microbiome because of antibiotic use.
Speaker:There's really a wide range of factors that are crucial for
Speaker:understanding how SIBO happens and how we can diagnose it and treat it.
Speaker:Okay.
Speaker:So it's going to predominantly sort of affect people who are already in a, I
Speaker:suppose you would say, a diseased state.
Speaker:But when sort of, I suppose, treating it In a traditional sense, what you
Speaker:would normally do is you would go to your, uh, your physician and you would
Speaker:do a traditional breath test there.
Speaker:Try and sort of analyze which of the forms of SIBO is present.
Speaker:And I suppose this is where OMED comes in and specifically the
Speaker:technology you've helped to develop.
Speaker:How is this different to how you would normally, uh, work with your
Speaker:physician and treat this condition?
Speaker:Um, how does the technology work and what is it that You're providing
Speaker:that it's perhaps different from the status quo, the norm, right?
Speaker:So, if you consider, for example, um, the case of the UK, we have a system
Speaker:that is heavily burdened by a lot of complexity in terms of, um, dictated
Speaker:by, The investment of government budgets and things that, like, for example,
Speaker:the COVID 19 pandemic that have caused further burdens onto the system.
Speaker:And you have this amount of people that suffer from GI conditions and GI
Speaker:symptoms, millions of them, every day.
Speaker:They struggle to find access to even diagnostic tests for conditions
Speaker:that could be SIBO, could be IMO, could be something else.
Speaker:And, and that's where OMED comes, um, into play.
Speaker:We provide this device that is a point of care portable device, which is precise
Speaker:and, um, overlaps very nicely in terms of preciseness with, with in clinic
Speaker:devices that cost millions of pounds.
Speaker:Um, and this, a, a fraction of the price can allow you to, to measure
Speaker:accurately, um, gases like hydrogen and methane that we know are involved,
Speaker:um, in conditions like SIBO and IMO.
Speaker:Okay.
Speaker:And, uh, the, the goal of OMED is to provide this platform that
Speaker:aims to transform how we normally manage gastrointestinal disorders.
Speaker:And, and the focus is, is being accessible, quick.
Speaker:Non invasive, allowing the patient and their medical practitioner to
Speaker:monitor their clinical status almost in real time, which is something that
Speaker:doesn't really happen at the moment.
Speaker:And behind this technology is the technology of breath testing that
Speaker:Owlstone has developed over the years and led us to become the
Speaker:leaders in breath analysis worldwide.
Speaker:And for example, if you look at SIBO, at the moment, There's a, a big long
Speaker:wait for you to access a specialized care for even the diagnostic of, um, uh,
Speaker:functional, uh, gastrointestinal disorder.
Speaker:If there's the availability of a device or a test that can provide a diagnosis or
Speaker:the monitoring component almost in real time, that leads the physician in care to
Speaker:understand how their interventions have an effect on the levels of the gases, on
Speaker:the symptoms and on the patient's general
Speaker:clinical status.
Speaker:This is a technology that is fundamental for streamlining care for individuals
Speaker:that suffer from GI symptoms every day.
Speaker:Okay.
Speaker:And is this a sort of a direct to consumer device or is this something
Speaker:that people are having to sort of work with their physicians to sort of acquire?
Speaker:Is it, um, are you able to just pick one up or, again, is it something
Speaker:that you would, uh, Maybe go and see your, your PCP and then work with
Speaker:them utilizing this piece of kit.
Speaker:Yeah, so at the moment, we're working together with, uh, industry leaders, with,
Speaker:with gastroenterologists and other, other, um, healthcare practitioners to help them
Speaker:with the monitoring of their patients.
Speaker:So.
Speaker:As things stand now, to acquire the device, uh, to acquire the
Speaker:OMED breathalyzer, you would have to go through your practitioner.
Speaker:But the future allows us to, uh, provide this directly to consumer, um, if we want.
Speaker:This is a, uh, like I mentioned, it's a precise device that allows you to,
Speaker:comparatively to an in clinic piece of machinery that costs millions of pounds.
Speaker:measure accurately your levels, allows you to record your symptoms, allows
Speaker:you to record your lifestyle, your levels of stress, your sleep, uh, your
Speaker:exercise, um, and, and even your diet.
Speaker:And, and this almost real time monitoring component is essential for you to
Speaker:understand how any intervention that you take, any modification that you do.
Speaker:on yourself and your diet, for example, uh, if it has any impact, uh, in, in
Speaker:the levels of your gases and ultimately on the underlying cause, which is SIBO.
Speaker:I'd like to backtrack quickly and just sort of, uh, maybe discuss in
Speaker:a bit more in, in depth what the difference between your various types
Speaker:of gases is and how they would present, present differently in terms of
Speaker:symptoms or what that actually means.
Speaker:I think we've, uh, talked about a few times You get a methane, you get
Speaker:hydrogen, and if I'm correct, you also get a hydrogen sulfide form of SIBO.
Speaker:But when it comes to the nuts and bolts, but maybe how does that
Speaker:sort of alter either treatment or how does that alter the diagnosis?
Speaker:So when you look at the gases, the gases are ultimately produced
Speaker:predominantly by the organism that is underlying the cause of your symptoms.
Speaker:So if you look at SIBO, SIBO is, like I've mentioned, an overabundance of bacteria.
Speaker:And there's specific bacteria that tend to produce hydrogen when they
Speaker:get into contact with substrates.
Speaker:So anything that comes in your food that doesn't get absorbed goes on
Speaker:to that, to those bacteria, become essentially their own food and lead
Speaker:them to produce hydrogen, which in large amounts can lead to symptoms such as
Speaker:bloating, flatulence, abdominal pain.
Speaker:And this is for SIBO alone, but if you look at gasses like methane, methane is
Speaker:traditionally produced by an organism called archaea, which is not a bacteria.
Speaker:It tends to exist across your whole GI tract.
Speaker:Um, some people more than others have, uh, lateral preponderance of archaea in their
Speaker:body, so they become producers of methane.
Speaker:Uh, so when exposed to certain types of substrate from your food,
Speaker:essentially, it will lead to the production, the production of, of
Speaker:methane via the metabolism of hydrogen.
Speaker:So there's these complex biochemical pathways in the microbiome where
Speaker:different gases are produced, uh, ones directly from a metabolism of food,
Speaker:others from metabolism of other gases.
Speaker:But essentially, what all these gases have in common, and regardless of the organism
Speaker:that produces them, is that their quantity and the way that they act on the, on the
Speaker:intestinal wall will drive the symptoms that are, that affect millions of people.
Speaker:One of the most, uh, known differences, if you, when you talk about hydrogen
Speaker:and methane, for example, is that people traditionally associate
Speaker:methane with, uh, IBS, uh, with constipation, which is something
Speaker:that's been shown in the literature.
Speaker:Higher levels of methane are associated with a slower GI
Speaker:tract that leads to constipation.
Speaker:So it's something that's been observed in IBS, for example.
Speaker:Um, and higher levels of hydrogen have been, uh, observed.
Speaker:But for example, in cases of patients that have a faster
Speaker:GI tract leading to diarrhoea.
Speaker:But there, there is a large overlap in the symptoms of these conditions and
Speaker:probably explains why they tend to be agglomerated under the name of SIBO alone.
Speaker:So, would you then say that, uh, SIBO sort of almost forms the, the base
Speaker:of a lot of these other GI disorders like, uh, IBD, IBS, Crohn's, Ulcerative
Speaker:Colitis, is there always going to be an element of SIBO in these individuals
Speaker:or are they too sort of, can they be very distinct from one another?
Speaker:I would err on the side of caution is saying always, always will be
Speaker:SIBO or IMO in those individuals.
Speaker:We know that a large frequency of, um, of SIBO exists in IBS.
Speaker:So we know that people that have IBS very frequently have, uh,
Speaker:SIBO underlying undiagnosed.
Speaker:And until they're diagnosed and treated, their symptoms are not
Speaker:appropriately managed, uh, regardless of the intervention that they take.
Speaker:And we know that SIBO is related to, um, other, uh, medical conditions, other
Speaker:functional and motility disorders, immune disorders, and, and endocrine disorders.
Speaker:I wouldn't say that, particularly when you try to associate with other
Speaker:GI conditions that, um, are very hard to diagnose, like IBS, uh, I wouldn't
Speaker:say that this is the sole cause, but it is, it is a large contributor, yes.
Speaker:Okay, then I suppose the next step is to discuss how you are sort of suggesting
Speaker:physicians go about treating SIBO.
Speaker:What is, I mean, again, a lot of physicians will sort of utilize
Speaker:antibiotics as their sort of first port of call, something like Rifampicin.
Speaker:Um, Rifaximin, I think it's called, but are you sort of advocating
Speaker:for a more natural approach?
Speaker:Are you sort of very much looking into drugs as a treatment opportunity
Speaker:or how are you at OMED going about, uh, yeah, with the supportive side
Speaker:of it, treating it specifically?
Speaker:So at OMED and at Owlstone um, as a whole, we tend to base our approach
Speaker:always backed by, uh, scientific evidence.
Speaker:And, um, the problem sometimes with the evidence surrounding conditions of, uh,
Speaker:gut gut brain disorders, for example, Is that, uh, the quality, um, is not
Speaker:always the best, the quality of the evidence, and, and the studies that are
Speaker:conducted are relatively underpowered.
Speaker:However, there is, there is a mainstay of therapy for SIBO and, and IMO,
Speaker:where we tend to treat, try to treat the underlying cause where applicable.
Speaker:Antibiotics is, uh, a large contributor to eradicating, uh, the condition.
Speaker:And then, um, treating nutritional deficiencies, identifying trigger
Speaker:foods is a big component as well of the treatment of SIBO.
Speaker:So things like antibiotics, as you mentioned, Rifaximin is, um, the, the
Speaker:main antibiotic we use to treat SIBO.
Speaker:Um, and IMO as shown as the best quality of evidence in terms of treatment for
Speaker:eradicating, eradicating this condition.
Speaker:But things like, for example, diet interventions.
Speaker:Uh, obviously, uh, a big, uh, contributor to identifying trigger
Speaker:foods, identifying tolerances, and try to create personalized, uh, diets long
Speaker:term that are balanced and allow for, um, um, someone that ha that suffers
Speaker:from GI symptoms to manage their condition without recurrently having to,
Speaker:go to antibiotics to get rid of SIBO.
Speaker:Diet alone has been shown, for example, to starve the bacteria that cause SIBO.
Speaker:So if we, if you take a targeted approach to identify and restrict the trigger,
Speaker:the trigger ingredients, then you can successfully manage long term disease.
Speaker:In terms of when you look at how we, we manage it at Owlstone, we tend to focus
Speaker:our component on the low FODMAP diet.
Speaker:We, we see the benefit in the literature of the low FODMAP in the treatment
Speaker:of IBS and the treatment of SIBO.
Speaker:Um, and low FODMAP involves Reducing certain, uh, amounts of fermentable,
Speaker:uh, fermentable carbohydrates.
Speaker:They tend to be associated with symptoms, uh, such as bloating, and,
Speaker:and flatulence and abdominal pain.
Speaker:And in, again, in numerous studies this has been shown to help alleviate
Speaker:symptoms by, by starving the bacteria and the organisms that produce
Speaker:the, these, uh, gases in excess.
Speaker:And in your experience, when somebody's following one of these diets, whether
Speaker:it be a sort of a low FODMAP diet, or potentially something like a ketogenic
Speaker:paleo diet, or some form of elimination diet, Are they at some point then
Speaker:able to reintroduce a lot of the foods that they were previously eating?
Speaker:Or does this become their quote unquote new normal?
Speaker:Are they then sort of stuck with this way of eating to sort of remain in a state of,
Speaker:uh, in a SIBO free state going forwards?
Speaker:Or is the idea to then sort of allow an in an individual to reintroduce
Speaker:foods, uh, that they were, that they were otherwise partial to or just form
Speaker:a, generally a large part of their day?
Speaker:Diet on a day-to-day basis.
Speaker:Yeah, that's a great question.
Speaker:So, uh, one of the problems with these restrictive diets is that when they are
Speaker:continued for a long time, they tend to lead to nutritional deficiencies because
Speaker:they are quite restrictive in the way, in the approach that we take for, for
Speaker:trying to identify these trigger foods.
Speaker:I think the goal of low FODMAP and other similar diets is The restrictive
Speaker:part has to be long enough to allow us, uh, to take away, uh, a big group of
Speaker:foods, but short enough that doesn't cause a tremendous impact on the, on
Speaker:the clinical status of the patient.
Speaker:So we don't want to cause, uh, nutritional deficiencies.
Speaker:But there is a component for reintroduction and the reintroduction
Speaker:part is very important.
Speaker:It's not just to identify What gives you symptoms, but also to identify the
Speaker:tolerance levels of certain certain foods So you might have you might be
Speaker:okay to consume certain Carbohydrates, for example when you talk about the
Speaker:low FODMAP diet You might consume a certain carbohydrates with minimal to
Speaker:no symptoms, but then when you go to increased servings, there might be quite,
Speaker:uh, quite a lot of symptoms for you.
Speaker:And you might be okay with that, with constructing your diet around
Speaker:that, to have limited amounts of those particular trigger foods.
Speaker:Uh, always present in your diet but at a limit that allows you to,
Speaker:to go about with your day with no impact in terms of, uh, of symptoms.
Speaker:But there's, the, the goal is to always test this reintroduction, this tolerance
Speaker:level occasionally because we know from, for example, allergy studies that
Speaker:things tend to change along the way across, across the span of several years.
Speaker:Your tolerance levels to certain foods in things like IBS and and SIBO will vary.
Speaker:So your diet has to become, has to be modulated around that.
Speaker:It has become relatively flexible for you to test these, these foods along the way,
Speaker:trying to make sure that your tolerances increase in the way that your diet remains
Speaker:balanced and you're not going to a very restrictive pattern that it'll eventually
Speaker:might get rid of SIBO, but will give you other problems.
Speaker:Yeah, create nutritional deficiencies along the way.
Speaker:If, if carbohydrates are essentially what are sort of, well in part, um, driving,
Speaker:uh, a number of these conditions, then why not just sort of take a sort of a shotgun
Speaker:approach potentially, and then just use something like a ketogenic diet, which
Speaker:will sort of remove well all simple sugars and all complex sugars from the equation.
Speaker:What are your thoughts on sort of a ketogenic approach, and
Speaker:why, how does it differ from a low, the low FODMAP approach?
Speaker:So if you look at a low FODMAP, it's not, it's not just carbohydrates
Speaker:that are involved, and they have been shown to cause symptoms
Speaker:in people with IBS and SIBO.
Speaker:I'm not very experienced with, uh, the ketogenic diet as a whole, but I know
Speaker:that the evidence for things like IBS and SIBO is relatively, there's a relatively
Speaker:unclear role for, for using it long term.
Speaker:Now, we know that, for example, with FODMAPs, which are the, uh, low
Speaker:fermentation, uh, low fermentable oligod and monosaccharides and
Speaker:polyols uh, we know that these, are things that are poorly absorbed and
Speaker:are osmotically active, and they go along the intestinal tract, and they
Speaker:get fermented by these bacteria.
Speaker:So, if you have a microbiota that is not imbalanced and is dysbiotic,
Speaker:we know that this will drive those bacteria that predominate and dominate
Speaker:over others to increasing numbers and increasing places where they shouldn't be.
Speaker:So we know that a low FODMAP is something that has shown to improve
Speaker:bloating and gas in patients with IBS, with SIBO, and there's evidence
Speaker:to support this in the prevention and management of patients long term.
Speaker:But again, there has to be a lot of caution in terms
Speaker:of these restrictive diets.
Speaker:It has to always be done under the auspice of a dietician
Speaker:or a healthcare practitioner.
Speaker:to prevent it from, from treating one thing but causing further problems.
Speaker:Of course, and I think it's always, it should always be noted as you just said
Speaker:that any sort of intervention should be done under the guidance of a physician.
Speaker:When sort of treating these conditions, what are your thoughts on compounds
Speaker:like antimicrobials, like berberine, like colloidal silver to sort of
Speaker:further support the eradication of some of these underlying issues?
Speaker:Do you think these sort of more natural, um, remedies have their place,
Speaker:or would you just sort of prefer to stick to something like an antibiotic?
Speaker:I think there's a place for, for antimicrobials.
Speaker:There's definitely evidence for specific, uh, antimicrobials in general.
Speaker:They're proving their, their antimicrobial activity and,
Speaker:and other functions in the gut.
Speaker:Now, I'm, I'm, again, weary in terms of a blanket statement
Speaker:of using them across, uh, as a replacement, strictly a replacement
Speaker:for antibiotics, without discussing the benefits and the risks of both.
Speaker:The antimicrobials, the evidence that exists related to SIBO,
Speaker:is, uh, of poor quality.
Speaker:It is there, but it is relatively underpowered studies.
Speaker:So, there needs to be more research in these natural treatments for
Speaker:SIBO and IMO and IBS to allow us to confidently say this is something
Speaker:that we can offer alongside antibiotics or instead of antibiotics.
Speaker:But again, I'm not completely putting them away.
Speaker:I think there's a place for them, but it has to be on a case by case situation.
Speaker:And there are a number of other, uh, therapies and modalities currently
Speaker:being explored in this space.
Speaker:I know there's a lot to be said about limbic system retraining
Speaker:and looking at the vagus nerve and stimulating the vagal nerve.
Speaker:Is this something you've explored, uh, at all?
Speaker:Or is this a body of evidence you are in any way familiar with?
Speaker:And do you think that these approaches that maybe look at,
Speaker:from a gut brain perspective, it's more a brain gut take on it.
Speaker:So sort of reversing the order of operations as it were, do you think these
Speaker:modalities hold any promise or unless you're actually treating the underlying
Speaker:is pathogenesis, the right word, um, pathology of these other modalities,
Speaker:perhaps maybe a bit sort of weak in their, um, approach or just underpowered.
Speaker:Well, there's definitely a, a growing interest around this topic of gut
Speaker:brain s as being, uh, bidirectional.
Speaker:Not like you said, not just, uh, brain gut, but gut brain as well.
Speaker:And what we've seen in terms of research is we know that the mental, the mental
Speaker:health and anxiety and depression affect the way you perceive your symptoms and,
Speaker:and affect the existence of symptoms and the frequency in which they occur,
Speaker:uh, in, in specific populations.
Speaker:I think they hold promise, uh, for future integration within treatment protocols.
Speaker:Uh, things like, for example, retraining, uh, limbic system, vagal
Speaker:nerve stimulation, to address this neural regulation of gut function,
Speaker:uh, and this interaction between the microbiota and the gut brain axis.
Speaker:But again, the evidence is still very, very new, very scarce.
Speaker:There has to be more quality evidence, more, um, more studies done, conducted
Speaker:to, to see how this, this, this, uh, relationship is bidirectional and can be
Speaker:modulated both ways with effect on, on, on symptoms and eradication of disease.
Speaker:But again, I, I don't think this is a, a treatment of its own.
Speaker:It will always be something.
Speaker:As, um, used in conjunction with an eradication method.
Speaker:So it will be something to more manage symptoms long term.
Speaker:Or, uh, or manage symptoms when eradication is not possible, for example.
Speaker:Fair enough.
Speaker:Yeah, I suppose it's going to be always going to be more as an adjunct
Speaker:therapy and not just a monotherapy.
Speaker:Exactly.
Speaker:You mentioned, yeah, you mentioned the future a couple of minutes ago.
Speaker:Where do you sort of see the future of, of breath testing going?
Speaker:And, and maybe this is just purely speculation and, Uh, just something
Speaker:that's of interest to me, but do you sort of see breath testing maybe being
Speaker:used in the next five to 10 years and sort of a, in a metabolic sense, maybe
Speaker:as a tool to help navigate and determine certain cancers or at this point, do you
Speaker:think it's purely going to be kept in the realm of a sort of functional GI care?
Speaker:Oh no, no.
Speaker:I think, I think the future of breath testing is incredible.
Speaker:incredibly promising.
Speaker:Not just in in GI disease, but just across all areas of medicine.
Speaker:I think over the next 5, 10 years there's going to be significant advancements.
Speaker:Not, not just about the accuracy and make them completely translating onto
Speaker:in clinic methods, but also in the By making it accessible, like we do
Speaker:with the OMED Breathalyzer device, making it accessible for the masses to
Speaker:streamline care and reduce waiting lists.
Speaker:I think that there's, there's, that for instance, there's a great potential to
Speaker:use breath testing in, in early detection of metabolic diseases, as you said,
Speaker:um, in identifiying specific biomarkers related to metabolic dysfunction.
Speaker:Um, there's already ongoing research in the use of breath testing
Speaker:for, for, for cancer diagnostics.
Speaker:And this will revolutionize the way we, we screen and diagnose a range of diseases
Speaker:from, from cancer to liver disease.
Speaker:The, I think, The world is our oyster in terms of how we can apply these
Speaker:volatile organic compounds, VOCs and breath, to link with specific
Speaker:diseases and, and create these non invasive methods to diagnose and treat.
Speaker:I would be remiss if I didn't ask about probiotics, something that
Speaker:I probably should have touched on earlier and asked about.
Speaker:Do you think probiotics have any specific sort of Place in, again, in functional
Speaker:GI care and, and disease, or are they more or less sort of preventative?
Speaker:Uh, are they something that you would take prophylactically, do you think?
Speaker:And sort of, are your strain, are these sort of multi, multi
Speaker:formula sort of approaches or maybe a single strain approach?
Speaker:Do you think, do you have any thoughts on probiotics specifically?
Speaker:Yeah, so I think there's, there's, um, there's a role for both, for
Speaker:preventive and targeted care.
Speaker:Okay.
Speaker:Again, there's data on certain diseases like IBS.
Speaker:There's limits of data on, on, on probiotics and SIBO.
Speaker:Um, with, I think, there's recent meta analysis where they show, kind of, both
Speaker:ways, there's no significant difference with, um, the incidence of SIBO, uh, with
Speaker:probiotics compared to a control group.
Speaker:But I think there's a component that we've seen with, uh, with, uh, recent
Speaker:studies on probiotics in IBS and IBD.
Speaker:There's a component to use them as targeted therapy, but it will always
Speaker:be on, on a very bespoke situation with a particular patient and not, not
Speaker:like a mainstream approach to eradicate or even, or even prevent the disease.
Speaker:I think there's always There's always a component for prevention in terms of multi
Speaker:strain, of improving your gut microbiome.
Speaker:Particularly if you feel better taking it.
Speaker:And there's no side effects and it doesn't interact with anything that
Speaker:you take in terms of medication.
Speaker:Sure, I'm more than happy to advise people to take that approach and trying
Speaker:to get this balance between health and well being and control of disease.
Speaker:There's not enough studies out there yet for the targeted approach of probiotics.
Speaker:For to be able to standardize this treatment formulations to use in patients.
Speaker:I suppose that sort of naturally leads on to a quick discussion about prebiotics.
Speaker:Do you think prebiotics again have their place?
Speaker:Or is that very much sort of a case of adding fuel to the fire?
Speaker:Especially if there's sort of an underlying pathology again in
Speaker:the case of something like SIBO.
Speaker:Are these products helpful?
Speaker:Are they damaging?
Speaker:My view of the literature says oftentimes, um, I suppose this also
Speaker:falls into the FODMAP side of things that if you're adding in a prebiotic
Speaker:to somebody who's already in a diseased state, that it's probably
Speaker:just going to make the issue worse.
Speaker:But do you have a sort of an opinion on that or counter or yeah, what are
Speaker:your views on prebiotics as a whole?
Speaker:I think, I think there's a, there's again a benefit for prebiotics in terms
Speaker:of promoting gut health in general by stimulating the growth of beneficial
Speaker:bacteria, but again, as I said, It could be adding fuel to the fire, if we promote
Speaker:it in the diseased state, uh, where we have these specific organisms that feed
Speaker:on specific foods that are non digested.
Speaker:And if you're introducing several strains or a particular strain, you might tip
Speaker:the balance of the scale to another type of dysbiosis, and not necessarily to,
Speaker:to make it a eubiosis environment where everything works perfectly in your gut.
Speaker:I would be more wary in using it in the diseased state, in someone
Speaker:who has active SIBO, versus using it in someone that is looking to
Speaker:just improve their general health.
Speaker:Uh, because they, they occasionally have symptoms, they, they feel that
Speaker:their digestive function is not as good as it could be, and their metabolism
Speaker:is not as good as it could be.
Speaker:So I, I think there's, there's um, incorporating it in, in the diet
Speaker:can be a good and effective way to improve the gut health, but very
Speaker:wary of using it in diseased states.
Speaker:I suppose like everything, it is ultimately about just finding balance
Speaker:and utilizing the right tool and the right individual at the right time.
Speaker:Exactly right.
Speaker:I think before we close, I'd just like to, and again, a selfish question.
Speaker:I'd just like to pick up your brain a little bit about how you, knowing what
Speaker:you know and uh, and what you've studied and, uh, the clinic and yeah, how you
Speaker:incorporate these practices in your life.
Speaker:Do you sort of follow any specific dieting exercise regime?
Speaker:I hate the word biohacking.
Speaker:It's sort of almost become cult like.
Speaker:But do you sort of including any of those sorts of practices in
Speaker:your life to optimize your life?
Speaker:Yeah, it's just always interesting to hear it from the horse's mouth, so to speak.
Speaker:So I would love to say I practice what I preach about, but I'd be lying.
Speaker:Um, I, I, I tend to maintain, try and maintain a balanced lifestyle.
Speaker:So in terms of diet, uh, for years I followed the Mediterranean style diet
Speaker:because I'm Portuguese, but recently that, that, that has become very hard to
Speaker:achieve, but I tried to, it's all, again, like you said, it's all about balance.
Speaker:I try to include a bit of everything in my diet.
Speaker:I try to not restrict myself too much.
Speaker:'cause fortunately, I, I, I don't suffer from GI problems.
Speaker:So, uh, but I try to maintain my diet relatively balanced by
Speaker:including a bit of everything and, uh, not letting it tip to excess in
Speaker:a particular, in a particular part.
Speaker:Um, in terms of, uh, in terms of exercise, could do more, I, I, I enjoy hiking
Speaker:and climbing and, and occasionally, uh, I, I do that and, uh, it helps me to
Speaker:stay active and, uh, cardiovascular, um, cardiovascular exercise does me to,
Speaker:to, to feel a bit better about myself.
Speaker:I've, I've, I've attempted diets in the past, so something like periodic
Speaker:fasting, intermittent fasting.
Speaker:Which, which helps, but it's very difficult to maintain, um, long term.
Speaker:But, but there's, there's a lot of things that, that, that you could do, alongside
Speaker:of things like, for example, uh, specific diets, uh, specific treatment regimens,
Speaker:uh, uh, sorry, exercise regimens, and, and things like cold exposure, for example.
Speaker:But I think it's all about balance.
Speaker:As long, as long as you can find balance for you, cause, uh, it's not a one size
Speaker:fits all kind of thing, as long as you find balance for you and what works for
Speaker:you, and try and maintain that, don't let it tip towards one end of the scale, just
Speaker:try and, and, Allow a bit of everything.
Speaker:Don't restrict yourself too much because long term it's very hard
Speaker:to maintain and will probably, um, have worse consequences.
Speaker:But yeah, I think, I think I'm managing so far.
Speaker:But I, um, I'm definitely not, not, uh, practicing what I preach.
Speaker:So, uh, I'm not not the best example.
Speaker:No, well, I mean you are otherwise healthy.
Speaker:So if not, why not?
Speaker:But yeah, no, I couldn't agree more.
Speaker:Um, and just to sort of reinforce what you just said, this sort of
Speaker:concept of biochemical individuality is, uh, is very important.
Speaker:And I do find it fascinating that a lot of people in the influencer space Who sort of
Speaker:promote these very extreme diets, whether it be carnivore or vegan or ketogenic.
Speaker:They all, over time, you watch them, Paul Saladino, the individual who really
Speaker:pushed the carnivore diet for a long time, being a prime example of this,
Speaker:they always seem to come back to center, whether it's sort of reintroducing
Speaker:carbohydrates, reintroducing vegetables.
Speaker:Uh, practicing less fasting, uh, fasting is a stressor obviously in
Speaker:a, in a, in a therapeutic sense.
Speaker:Um, it's amazing, but only in the short term, uh, obviously with long term
Speaker:use, you're going to potentially create dysfunction in your HPA axis and creates
Speaker:all sorts of hormonal dysregulation there.
Speaker:So yeah, no, I couldn't agree more.
Speaker:It's, it's, it's ultimately about maintaining that sort
Speaker:of healthy middle ground.
Speaker:Where's the best place to find you and your company.
Speaker:Rui?
Speaker:I know you've mentioned both Owlstone and OMED for the consumer who's looking
Speaker:to potentially particularly purchase one of the, these breath analyzing, uh,
Speaker:products, where would you point them to?
Speaker:Yeah, so if, if you're interested in, in learning more, um, you can find
Speaker:regular updates and, and our latest research and developing in our websites.
Speaker:So generally about breath research at Owlstone Medical and, uh, more
Speaker:specifically about g the GI space, uh, OMED Health, so omedhealth.com.
Speaker:And owlstonemedical.com for detailed information about what we do and how
Speaker:we are advancing the field of breath based diagnostics and research.
Speaker:Um, I intend to, to publish some of those updates as well in latest research
Speaker:and developments in my LinkedIn.
Speaker:So if you feel free to contact me there.
Speaker:Okay, perfect.
Speaker:And we'll publish links to all of those socials and websites in the show notes
Speaker:as well as any other studies that we sort of either mentioned or discussed.
Speaker:or that I would think that the listener would otherwise find interesting in
Speaker:the, yeah, again, in the show notes.
Speaker:Thank you so much for your time.
Speaker:We really appreciate it.
Speaker:This has been enlightening.
Speaker:Definitely learned a lot and we'll have to get some points soon.
Speaker:Yeah, thank you.
Speaker:It's been great to be here.
Speaker:Thanks Rob.
